Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway

Identification of SYK inhibitor, R406 as a novel senolytic agent

(2020) Hyun-Ji Cho et al.   Aging-US

Characterization of clinically relevant model bacterial strains of Pseudomonas aeruginosa for anti-biofilm testing of materials

(2018) Olena Rzhepishevska et al.   Acta Biomaterialia

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

(2018) James Bussel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells

(2018) Manon Ruffin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Syk inhibitor R406 downregulates inflammation in an in vitro model of Pseudomonas aeruginosa infection

(2018) Alaa Alhazmi et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Current approaches to the discovery of novel inhaled medicines

(2018) Peter Strong et al.   DRUG DISCOVERY TODAY

Superior anti-inflammatory effects of narrow-spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive pulmonary disease

(2018) Jürgen Knobloch et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

(2018) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection

(2018) Alaa Alhazmi   Journal of Innate Immunity

FDA approves first-in-class SYK inhibitor

(2018) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial

(2018) Naimish Patel et al.   International Journal of Chronic Obstructive Pulmonary Disease

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease

(2018) Philip Scheltens et al.   Annals of Clinical and Translational Neurology

The anti-microbial peptide TP359 attenuates inflammation in human lung cells infected with Pseudomonas aeruginosa via TLR5 and MAPK pathways

(2017) Ejovwoke F. Dosunmu et al.   PLoS One

Spleen Tyrosine Kinase Induces MUC5AC Expression in Human Airway Epithelial Cell

(2016) Hyung Gyun Na et al.   American Journal of Rhinology & Allergy

Selumetinib in the treatment of non-small-cell lung cancer

(2016) Reyes Bernabé et al.   Future Oncology

Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma

(2016) Stuart T. Onions et al.   JOURNAL OF MEDICINAL CHEMISTRY

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells

(2015) Wing S To et al.   BRITISH JOURNAL OF PHARMACOLOGY

TLR4-mediated IRAK1 activation induces TNF-α expression via JNK-dependent NF-κB activation in human bronchial epithelial cells

(2015) Sae Hoon Park et al.   European Journal of Inflammation

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

(2015) Haakon B Nygaard et al.   Alzheimers Research & Therapy

Lung microbiota across age and disease stage in cystic fibrosis

(2015) Bryan Coburn et al.   Scientific Reports

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

(2014) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial

(2013) M. E. Weinblatt et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

(2013) William MacNee et al.   THORAX

Respiratory Syncytial Virus Infection Disrupts Monolayer Integrity and Function in Cystic Fibrosis Airway Cells

(2013) Michele Kong et al.   Viruses-Basel

Pseudomonas aeruginosa: new insights into pathogenesis and host defenses

(2013) Shaan L. Gellatly et al.   Pathogens and Disease

Atypical Activation of the Unfolded Protein Response in Cystic Fibrosis Airway Cells Contributes to p38 MAPK-Mediated Innate Immune Responses

(2012) C. J. Blohmke et al.   JOURNAL OF IMMUNOLOGY

MAP Kinase Pathways

(2012) D. K. Morrison   Cold Spring Harbor Perspectives in Biology

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

(2011) Praveen Anand et al.   EUROPEAN JOURNAL OF PAIN

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

(2011) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia

(2010) Alejandro A. Pezzulo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Mechanisms and functions of p38 MAPK signalling

(2010) Ana Cuadrado et al.   BIOCHEMICAL JOURNAL

Loss of Cystic Fibrosis Transmembrane Conductance Regulator Function Enhances Activation of p38 and ERK MAPKs, Increasing Interleukin-6 Synthesis in Airway Epithelial Cells Exposed toPseudomonas aeruginosa

(2010) Julie Bérubé et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

(2009) Nemanja Damjanov et al.   ARTHRITIS AND RHEUMATISM

Inhibition of p38: Has the fat lady sung?

(2009) Mark C. Genovese   ARTHRITIS AND RHEUMATISM

Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection

(2009) J. A. Van Ziffle et al.   BLOOD

Tyrosine Kinases and Inflammatory Signalling

(2009) Theresa Page et al.   CURRENT MOLECULAR MEDICINE

Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation

(2009) H. R. Hope et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin

(2009) P. Ceppi et al.   MOLECULAR CANCER THERAPEUTICS

Airway Inflammation in Cystic Fibrosis

(2008) Arnon Elizur et al.   CHEST

Neutrophils in cystic fibrosis

(2008) D G Downey et al.   THORAX